Two recent studies suggest that a subgroup of MS patients with high serum concentrations of IFN-β and IL-17F or with evidence of high expression levels of type I IFN-induced genes respond poorly to subsequent treatment with IFN-β [15,30]. The gene discussed is IL17F; the disease is myeloid sarcoma.